JP2023521219A5 - - Google Patents

Info

Publication number
JP2023521219A5
JP2023521219A5 JP2022562561A JP2022562561A JP2023521219A5 JP 2023521219 A5 JP2023521219 A5 JP 2023521219A5 JP 2022562561 A JP2022562561 A JP 2022562561A JP 2022562561 A JP2022562561 A JP 2022562561A JP 2023521219 A5 JP2023521219 A5 JP 2023521219A5
Authority
JP
Japan
Prior art keywords
seq
molecule
amino acid
hla
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521219A (ja
JP7822953B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/050340 external-priority patent/WO2021207823A1/en
Publication of JP2023521219A publication Critical patent/JP2023521219A/ja
Publication of JP2023521219A5 publication Critical patent/JP2023521219A5/ja
Priority to JP2025153952A priority Critical patent/JP2026009916A/ja
Application granted granted Critical
Publication of JP7822953B2 publication Critical patent/JP7822953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562561A 2020-04-14 2021-03-15 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 Active JP7822953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153952A JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009853P 2020-04-14 2020-04-14
US63/009,853 2020-04-14
PCT/CA2021/050340 WO2021207823A1 (en) 2020-04-14 2021-03-15 Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153952A Division JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2023521219A JP2023521219A (ja) 2023-05-23
JP2023521219A5 true JP2023521219A5 (enExample) 2024-02-29
JP7822953B2 JP7822953B2 (ja) 2026-03-03

Family

ID=78083452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562561A Active JP7822953B2 (ja) 2020-04-14 2021-03-15 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
JP2025153952A Pending JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153952A Pending JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Country Status (11)

Country Link
US (1) US20230287070A1 (enExample)
EP (1) EP4136099A4 (enExample)
JP (2) JP7822953B2 (enExample)
KR (1) KR20220167288A (enExample)
CN (1) CN115397842A (enExample)
AU (1) AU2021256477A1 (enExample)
BR (1) BR112022020376A2 (enExample)
CA (1) CA3173666A1 (enExample)
IL (1) IL296881A (enExample)
MX (1) MX2022012758A (enExample)
WO (1) WO2021207823A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
CN114045341B (zh) * 2021-11-30 2024-03-01 中南大学 口腔黏膜下纤维化恶性进展或其所致口腔癌的早期诊断和/或预后生物标志物的应用及产品
US20240013860A1 (en) * 2022-07-06 2024-01-11 Bioinformatics Solutions Inc. Methods and systems for personalized neoantigen prediction
EP4602051A1 (en) * 2022-10-11 2025-08-20 Université de Montréal Novel tumor-specific antigens for myeloid leukemia and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
EP2576614A4 (en) * 2010-05-24 2013-11-13 Phosimmune Inc CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
HRP20191671T1 (hr) * 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20200967T1 (hr) * 2014-06-20 2020-10-16 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP3277841A1 (en) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
US11524989B2 (en) * 2015-06-24 2022-12-13 Kling Biotherapeutics B.V. AML antigens and uses thereof
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202110335PA (en) * 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
TW201841937A (zh) * 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
MX2021002333A (es) * 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
TW202024121A (zh) * 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Similar Documents

Publication Publication Date Title
JP7559120B2 (ja) がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体
TWI764886B (zh) 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
JP6913032B2 (ja) 共通ネオ抗原
JP2023106599A5 (enExample)
JP2022527267A5 (enExample)
JP2022523552A5 (enExample)
JP2022524993A5 (enExample)
JP2022523554A5 (enExample)
JP2022524994A5 (enExample)
JP2022523971A5 (enExample)
JP2022523553A5 (enExample)
JP2022524992A5 (enExample)
AU2020231694A1 (en) T cell receptors and methods of use thereof
JP2020533962A5 (enExample)
JP2024535853A5 (enExample)
JP2022543059A5 (enExample)
CA3146298A1 (en) T cell receptors and methods of use thereof
CN114450414B (zh) T细胞受体及其使用方法
AU2020322247A1 (en) T cell receptors and methods of use thereof
JP2022543058A5 (enExample)
CN113929767B (zh) 具有高亲和力的t细胞受体及其用途
JP2024536647A (ja) 操作されたｔｃｒ複合体及びそれを使用する方法
JP2024527620A5 (enExample)
US20260042827A1 (en) Anti-wt1 antigen-binding proteins and uses thereof
Janik et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease